Skip to main content

Global partner of choice for oligonucleotide drug discovery and development programs

Partnering with us grants access to our proprietary oligonucleotide discovery and development platform OligoCreator®.

With our AI-empowered platform we can combine multiple delivery modalities to identify and characterize oligonucleotide therapeutics with unparalleled speed as well as excellent safety and efficacy, coffering the opportunity to generate real lead candidates within 6 - 12 months. By precisely delivering these novel therapeutics to specific cells, organs or tissues, targeted oligonucleotide therapeutics have the potential to revolutionize treatments for a wide range of difficult-to-treat disorders.

Discovery & Research Alliances

Our business model allows partners to engage in single or multiple asset collaborations using our OligoCreator® platform, enhancing project outcomes by capitalizing on the expertise and resources of all parties.

We welcome collaborations on existing projects and newly selected targets. Collaborate with Secarna, your strategic partner in oligonucleotide development. Together, we redefine the discovery and development of best-in-class oligonucleotide-based therapeutics.

get in touch

In-House Discovery & Development

We continuously launch and advance proprietary projects focused on novel oligonucleotide candidates, which are strategically structured to conveniently foster collaborations with external partners for development and commercialization.

LEARN MORE about OUR LEAD PROGRAM

Current Partnerships

Globally, we are the trusted partner of choice for best-in-class oligonucleotide therapeutics, consistently validated by our ongoing collaborations and partnerships with pharma, biotech and academia. Our track record shows that we can rapidly generate therapeutic candidates and pipelines in close collaboration with a partner’s R&D organization.

Our partners include: